The Effectiveness of Recombinant Zoster Vaccine: Observations in the Wild

Affiliations

Editorial

Rafael Harpaz. Clin Infect Dis. 2021.

. 2021 Sep 15;73(6):957-960.

doi: 10.1093/cid/ciab130.

¹ Harpaz Herman Consultants, LLC, US Public Health Service (USPHS), Atlanta, Georgia, USA.

No abstract available

Keywords: effectiveness; efficacy; immunocompromise; vaccines; zoster.

Comment on

Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.
Izurieta HS, Wu X, Forshee R, Lu Y, Sung HM, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, MaCurdy TE, Kelman J, Dooling K. Izurieta HS, et al. Clin Infect Dis. 2021 Sep 15;73(6):941-948. doi: 10.1093/cid/ciab125. Clin Infect Dis. 2021. PMID: 33580242
Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study.
Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Sun Y, et al. Clin Infect Dis. 2021 Sep 15;73(6):949-956. doi: 10.1093/cid/ciab121. Clin Infect Dis. 2021. PMID: 33580245 Free PMC article.